Advances in the Therapy of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in 2025

Authors

  • Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI Toronto Allergists, Toronto Allergy and Asthma Clinic, Evidence Based Medical Educator Inc, Toronto, ON, Canada Author
  • Christian Pagnoux, MD, MSc, MPH Vasculitis Clinic, Mount Sinai Hospital, Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada Author

DOI:

https://doi.org/10.58931/cret.2025.114

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis affecting small to medium-sized vessels, characterized by asthma, eosinophilia, and inflammation. Recent advances in the understanding of EGPA pathogenesis have facilitated the development of targeted therapies, particularly biologics, aimed at improving disease control and reducing treatment-associated toxicity. This review discusses the current therapeutic landscape for EGPA in 2025, highlighting key clinical trials, real-world data, and future directions.

Author Biographies

  • Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI, Toronto Allergists, Toronto Allergy and Asthma Clinic, Evidence Based Medical Educator Inc, Toronto, ON, Canada

    Dr. Jason Lee is a practicing physician specializing in immunotherapy treatment of allergic diseases, including allergic asthma, at Toronto Allergists in Toronto, ON, Canada, where he is also clinical director and managing partner. In addition, he is CEO of Evidence Based Medical Educator Inc in Toronto and the founder and chair of Urticaria Canada, an advocacy and patient support organization whose goal is to educate patients and health care professionals about chronic urticaria. Dr. Lee earned a Doctor of Medicine degree from the Faculty of Medicine at the University of Toronto. He subsequently received fellowship training in internal medicine at the University of British Columbia in Vancouver, Canada, and in clinical immunology and allergy at the University of Toronto. Dr. Lee’s research interests include asthma, urticaria, nasal polyps, chronic cough, and atopic dermatitis. Among his accomplishments is working on the national consensus guidelines on immunoglobulin replacement therapy for secondary immune deficiencies and co-authorship of the original first paper on the use of dupilumab for chronic spontaneous urticaria in patients who had failed to respond to omalizumab. Dr. Lee has served as section head of asthma at the Canadian Society of Allergy and Clinical Immunology and is currently a member of the Biologics and Therapeutics Committee of the American College of Allergy, Asthma, and Immunology.

  • Christian Pagnoux, MD, MSc, MPH, Vasculitis Clinic, Mount Sinai Hospital, Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada

    Dr. Pagnoux trained in internal medicine and clinical immunology in Paris (France). Between 2002 and 2010, he worked in Paris and has served as vice‑president of the French Vasculitis study group. He moved to Toronto (Canada) in 2010 and was appointed in the Division of rheumatology at the Mount Sinai Hospital. He joined the steering committee of the North American Vasculitis Clinical Research Consortium (VCRC), and founded CanVasc, the Canadian network for research in vasculitis. He has been involved in many important studies in vasculitis, led by the French, European or North-American groups, has written or co-authored more than 300 peer-reviewed publications and several textbook chapters on vasculitis.

References

Makhzoum JP, Grayson PC, Ponte C, Robson J, Suppiah R, Watts RA, et al. Pulmonary involvement in primary systemic vasculitides. Rheumatology (Oxford). 2021;61(1):319-330. doi:10.1093/rheumatology/keab325

Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63(2):65-81. doi:10.1097/00005792-198403000-00001 https://pubmed.ncbi.nlm.nih.gov/6366453/

Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau, T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638-1645. doi:10.1002/art.1780381116.

Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463-473. doi:10.1038/nrrheum.2014.103

Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford C, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi:10.1056/NEJMoa1702079.

Bettiol A, Urban ML, Dagna L, Cottin V, Franceschini F, Del Giacco S, et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: a european multicenter observational study. Arthritis Rheumatol. 2022;74(2):295-306. doi:10.1002/art.41943

Moosig F, Bremer JP, Hellmich B, Ulrike Holle J, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-1017. doi:10.1136/annrheumdis-2012-201531/

Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis [published correction appears in J Allergy Clin Immunol. 2021 Jun;147(6):2394. doi: 10.1016/j.jaci.2021.03.023.]. J Allergy Clin Immunol. 2019;143(6):2170-2177. doi:10.1016/j.jaci.2018.11.041

Watanabe R, Hashimoto M. Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations. J Clin Med. 2023;12(18):5996. doi:10.3390/jcm12185996

Padoan R, Davanzo F, Iorio L, Saccardo T, Roccuzzo G, Zampollo S, et al. Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis. Rheumatology. 2024; keae554. https://doi.org/10.1093/rheumatology/keae554

Springer JM, Funk RS. Dose-dependent pharmacological response to rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2021;48(11):1718-1724. doi:10.3899/jrheum.210361

van der Goes MC, Jacobs JW, Boers M, Blom-Bakkers MAM, Buttgereit F, Caeyers N, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913-1919. doi:10.1136/ard.2009.124958

Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429-1441. doi:10.1183/13993003.00097-2016

White J, Dubey S. Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev. 2023;22(1):103219. doi:10.1016/j.autrev.2022.103219

Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. doi:10.1038/s41572-020-0204-y

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30-47. doi:10.1136/ard-2022-223764

Samson M, Devilliers H, Thietart S, Charles P, Pagnoux C, Cohen P, et al. Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. 2023;9:e002953. doi: 10.1136/rmdopen-2022-002953

Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. World Allergy Organ J. 2022;15(8):100676. doi:10.1016/j.waojou.2022.100676

Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract. 2015;3(2):167-174. doi:10.1016/j.jaip.2015.01.013

Downloads

Published

2025-05-15

Issue

Volume 1, Issue 1, Spring 2025

Section

Articles

How to Cite

Advances in the Therapy of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in 2025. (2025). Canadian Respirology Today, 1(1), 20–25. https://doi.org/10.58931/cret.2025.114